LON:AVO - Advanced Oncotherapy Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 52.57 -0.93 (-1.74 %)
(As of 05/21/2018 07:20 AM ET)
Previous CloseGBX 53.50
Today's RangeGBX 52 - GBX 55
52-Week RangeGBX 9.75 - GBX 64.80
Volume62,486 shs
Average Volume79,755 shs
Market Capitalization£41.31 million
P/E RatioN/A
Dividend YieldN/A

About Advanced Oncotherapy (LON:AVO)

Advanced Oncotherapy logoAdvanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. It is involved in developing Linac Image Guided Hadron technology, a proton therapy system for treating cancer. The company is also involved in the management of a healthcare related property. It operates in the United Kingdom, Switzerland, and the Unites States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy PLC was incorporated in 2005 and is headquartered in London, the United Kingdom.

Receive AVO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Devices


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-43.18%
Return on Assets-35.03%


Outstanding Shares80,940,000

Advanced Oncotherapy (LON:AVO) Frequently Asked Questions

What is Advanced Oncotherapy's stock symbol?

Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO."

Who are some of Advanced Oncotherapy's key competitors?

Who are Advanced Oncotherapy's key executives?

Advanced Oncotherapy's management team includes the folowing people:
  • Dr. Michael Jeffrey Sinclair, Exec. Chairman (Age 75)
  • Mr. Nicolas Serandour, CEO & Exec. Director
  • Dr. Sanjeev Pandya, Exec. VP for Global Bus. Devel. and Exec. Director
  • Mr. Ed Lee, COO & Sr. VP of Operations
  • Mr. Graham Pughe, Sr. VP of Accounting & IT

Has Advanced Oncotherapy been receiving favorable news coverage?

Press coverage about AVO stock has been trending somewhat positive on Monday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Advanced Oncotherapy earned a coverage optimism score of 0.05 on Accern's scale. They also gave news coverage about the company an impact score of 47.47 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Advanced Oncotherapy?

Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Advanced Oncotherapy's stock price today?

One share of AVO stock can currently be purchased for approximately GBX 52.57.

How big of a company is Advanced Oncotherapy?

Advanced Oncotherapy has a market capitalization of £41.31 million.

How can I contact Advanced Oncotherapy?

Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728.

MarketBeat Community Rating for Advanced Oncotherapy (AVO)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  312
MarketBeat's community ratings are surveys of what our community members think about Advanced Oncotherapy and other stocks. Vote "Outperform" if you believe AVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Advanced Oncotherapy (LON:AVO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AHoldHold
Consensus Rating Score: N/AN/A2.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A

Advanced Oncotherapy (LON:AVO) Consensus Price Target History

Price Target History for Advanced Oncotherapy (LON:AVO)

Advanced Oncotherapy (LON:AVO) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
2/27/2017Beaufort SecuritiesDowngradeHoldView Rating Details
(Data available from 5/21/2016 forward)



Advanced Oncotherapy (LON:AVO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Advanced Oncotherapy (LON AVO) Insider Trading and Institutional Ownership History

Insider Trading History for Advanced Oncotherapy (LON:AVO)

Advanced Oncotherapy (LON AVO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/11/2018Enrico Cipro VanniInsiderBuy40,000GBX 55£22,000
7/31/2017Enrico Cipro VanniInsiderBuy100,000GBX 18£18,000
5/15/2017Steve Myers OBEInsiderBuy400,000GBX 26£104,000
5/9/2017Christopher NuttingInsiderBuy202,500GBX 25£50,625
4/25/2017Michael J SinclairInsiderBuy200,000GBX 30£60,000
4/24/2017Enrico Cipro VanniInsiderBuy100,000GBX 27£27,000
4/12/2017Enrico Cipro VanniInsiderBuy100,000GBX 28£28,000
4/4/2017Enrico Cipro VanniInsiderBuy25,000GBX 29£7,250
4/3/2017Michael J SinclairInsiderBuy100,000GBX 28£28,000
1/3/2017Enrico Cipro VanniInsiderBuy25,000GBX 87£21,750
12/29/2016Enrico Cipro VanniInsiderBuy25,000GBX 66£16,500
12/22/2016Enrico Cipro VanniInsiderBuy25,000GBX 60£15,000
12/20/2016Enrico Cipro VanniInsiderBuy25,000GBX 55£13,750
12/19/2016Enrico Cipro VanniInsiderBuy25,000GBX 50£12,500
7/11/2016Bradfield ,MichaelInsiderBuy30,000GBX 135£40,500
7/8/2016Bradfield ,MichaelInsiderBuy10,000GBX 120£12,000
7/7/2016Bradfield ,MichaelInsiderBuy10,000GBX 112£11,200
7/6/2016Bradfield ,MichaelInsiderBuy50,000GBX 102£51,000
12/18/2015Bradfield ,MichaelInsiderBuy750,000GBX 7£52,500
12/17/2015Bradfield ,MichaelInsiderBuy1,000,000GBX 6£60,000
12/16/2015Bradfield ,MichaelInsiderBuy750,000GBX 6£45,000
7/20/2015Vanni ,Enrico CiproInsiderBuy1,000,000GBX 8£80,000
7/1/2015Sinclair,Michael JInsiderSell7,000,000GBX 0.08£5,600
6/5/2015Michael BradfieldInsiderBuy1,500,000GBX 9.81£147,150
2/4/2015Michael BradfieldInsiderBuy500,000GBX 4.10£20,500
(Data available from 1/1/2013 forward)


Advanced Oncotherapy (LON AVO) News Headlines


SEC Filings

Advanced Oncotherapy (LON:AVO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.


Financials are not available for this stock.


Advanced Oncotherapy (LON AVO) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.